Design Therapeutics opened lower at $10.61, compared with its previous close of $10.77. In the last trading session, the stock traded between $10.27 and $10.88. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Design Therapeutics is now worth
$ 52.22
Resulting in a loss of
$ 47.78 (47.78%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.18 (-1.62%)
Day High
$10.88
Day Low
$10.27
Day Open
$10.61
Prev Close
$10.77
Volume
4,12,068
1W Return
-0.34%
1M Return
-2.90%
3M Return
-27.46%
6M Return
-32.13%
1Y Return
36.53%
Fundamentals
Market Cap ($ Mn)
678
PE Ratio
-
PB Ratio
4.68
PEG Ratio
-
ROE
-31.86%
ROCE
-36.10%
EPS (TTM)
$-0.32
Investment Returns
1 Week
-0.34%
1 Month
-2.90%
3 Months
-27.46%
6 Months
-32.13%
9 Months
2.27%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
RBC lowers Design Therapeutics price target to $19, keeps Outperform
RBC Capital lowered the price target for Design Therapeutics from $20 to $19. The firm maintained an Outperform rating on the stock. Analyst Leonid Timashev authored the rating update.
7 days ago
5Nov
Design Therapeutics authorizes $200M stock sales through Jefferies
Design Therapeutics authorizes up to $200 million in common stock sales. New ATM program executed through Jefferies. Supplements existing $300 million mixed shelf offering. Proceeds earmarked for general corporate purposes.
8 days ago
3Aug
Design Therapeutics Q2 Results: EPS beats estimates with narrower losses
Design Therapeutics delivered Q2 EPS of $(0.32), beating the $(0.34) estimate by 5.88%. This compares favorably to the $(0.34) loss in the prior year period, showing a trend toward narrower losses despite continued unprofitability.
3mo ago
30Jun
Design Therapeutics begins DT-818 dosing in Phase 1 DM1 trial
Design Therapeutics initiates patient dosing in Phase 1 MAD trial of DT-818 for myotonic dystrophy type-1. DT-818 is a GeneTAC small molecule targeting the mutant DMPK allele to address the disease's root cause.
